Gerald H. Moeller

Dr. Gerald Moeller has more than 40 years of management experience in the diagnostic, pharmaceutical and MedTech industries. From May 2002 to April 2014 he was an Investment Advisor to HBM Partners, Zug/Switzerland. As an active participant in the international healthcare / biotechnology sector Dr. Moeller served on the board of companies such as Bionostics Inc (Director), BRAHMS AG (Chairman); Definiens AG (Chairman); Febit AG (Chairman); Genticel SA (ViceChairman), Ikonisys Inc (Director); Illumina Inc (Director); MTM Laboratories AG (Chairman); Invendo-Medical GmbH (Chairman); Pelikan Inc (Chairman); PowderJect Pharmaceuticals Plc (Chairman); Strakan Ltd (Chairman); Vivacta Ltd (Director) and Sugen Inc (Director). Sugen Inc, PowderJect Plc; MTM Laboratories AG, BRAHMS AG, Vivacta Ltd, Bionostics Inc, Definiens AG and Invendo-Medical GmbH were successfully sold to large global HealthCare companies.

From 2003 to 2016 Dr Moeller also served as Chairman of FIND (Foundation for Innovative New Diagnostics), a PDP with the Bill and Melinda Gates Foundation. In May 2018 Dr Moeller resigned from the Board of Directors of Morphosys AG after 19 years of Service as Chairman. Today he serves on the Board of 4Sigma GmbH,Germany (Chairman); (Healthcare Services) Sphingotec GmbH, Germany (ViceChairman) 4teen4 GmbH, Germany, (Director) DIADEM DX, Italy, (Chairman).

Dr Möller cofounded Adrenomed AG, a Biopharmaceutical company, served as Vice Chairman, from 12/17 to 8/19 as CEO and since 12/19 as Director. From 1975-1998, Dr. Moeller held several senior level positions in Germany, Japan, USA and the Netherlands with Boehringer Mannheim, including: Head of R&D Diagnostics; President of Decentralized Diagnostics; CEO of Boehringer Mannheim Therapeutics; and Chief Technology Officer of Corange, the holding company of Boehringer Mannheim. In 1995 he became CEO of the worldwide Boehringer Mannheim Group, which generated sales of >$4 billion in 1997. Following the sale of Boehringer Mannheim Group to Roche in 1998, Dr. Moeller was named Head of Global Development and Strategic Marketing Pharmaceuticals, as well as a member of Roche’s Executive Committee. Dr. Moeller left Roche in December 1998. Dr. Moeller received his Ph.D. in Physical Chemistry from the University of Kiel, Germany.